中性粒细胞与淋巴细胞比值与帕博利珠单抗治疗口咽癌的生存关系
结果发现,较高的治疗前NLR与较差的6个月PFS和2年OS相关,且该关联仅在p16阳性患者中显著。
要点
- 治疗前高NLR与帕博利珠单抗治疗口咽癌患者较差的6个月PFS和2年OS相关。
- NLR与生存的关联仅在p16阳性患者中显著,p16阴性患者中不显著。
- 治疗前NLR或可作为预测免疫治疗获益的生物标志物,但需进一步验证。
核心结论
- 较高的治疗前NLR与接受帕博利珠单抗治疗的复发/转移性口咽鳞状细胞癌患者较差的6个月PFS和2年OS相关。
- 按p16状态分层后,该关联仅在p16阳性患者中保持显著。
研究设计与样本
- 主要结局为6个月无进展生存,次要结局为2年总生存;NLR作为连续变量和二分类变量分析。
- 疾病进展采用实体瘤疗效评价标准(RECIST)的影像学标准判定。
主要发现
- NLR作为连续变量时,较高的治疗前NLR与较差的6个月PFS相关[HR 1.14(1.03,1.27),p=0.016]。
- NLR作为连续变量时,较高的治疗前NLR与较差的2年OS相关[HR 1.21(1.09,1.35),p=0.001]。
- p16阳性患者中,NLR与较差的生存相关[HR 1.16(1.00,1.33),p=0.046];p16阴性患者中关联不显著[HR 1.11(0.94,1.31),p=0.203]。
临床怎么用
- 对于接受帕博利珠单抗治疗的复发/转移性口咽鳞状细胞癌患者,治疗前可考虑计算NLR以辅助预后分层。
- p16阳性患者中NLR的预后价值更明显,可能有助于识别免疫治疗获益较低的人群。
局限性
- 原文未报告NLR二分类分析的具体阈值及结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A minority of patients receiving immunotherapy for oropharyngeal head and neck squamous cell carcinoma benefit. Finding biomarkers that predict response to ICI is important for improving outcomes in these patients. In this study, we determine the relationship between pretreatment neutrophil-to-lymphocyte ratio (NLR) and 6-month progression-free survival (PFS)/2-year overall survival (OS) among patients with recurrent or metastatic (R/M) oropharyngeal cancer on pembrolizumab. METHODS: This study was a retrospective cohort study of patients with recurrent/metastatic OPSCC who were treated with pembrolizumab between May 2016 and May 2022 at a tertiary care academic center. The primary outcome was 6-month progression-free survival. The secondary outcome was 2-year overall survival. NLR was treated as a continuous and dichotomous variable. Disease progression was determined using radiographic criteria adopted from the Response Evaluation Criteria in Solid Tumors. RESULTS: Sixty-four patients with OPSCC were included. The median pre-treatment NLR was 5.1 (IQR 3.1-8.3). Thirty-seven (58%) patients had distant metastases at the start of ICI. When treated as a continuous variable, higher pretreatment NLR was associated with poorer 6-month PFS [HR 1.14 (1.03, 1.27), p = 0.016] and 2-year OS [HR 1.21 (1.09, 1.35), p = 0.001] for patients on pembrolizumab. Subgroup analyzes on patients who were p16+ versus p16- revealed that NLR was only associated with poorer survival for p16+ patients [HR 1.16 (1.00, 1.33), p = 0.046 versus HR 1.11 (0.94, 1.31), p = 0.203, respectively]. CONCLUSION: Higher pretreatment NLR was associated with poorer 6-month PFS and 2-year OS in OPSCC patients treated with pembrolizumab. When stratified by p16 status, this association only remained significant among p16+ patients.
引用
- Truong AA, Ho S, Lee RH, et al. Neutrophil-To-Lymphocyte Ratio and Survival in Pembrolizumab-Treated Oropharyngeal Cancer. Head Neck. 2026. PMID: 42108213. doi:10.1002/hed.70312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。